Drug Profile
LY 3002815
Alternative Names: LY3002815Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Unspecified in USA (IV, Injection)
- 09 May 2017 Preclinical trials in Undefined indication in USA (IV) before May 2017
- 09 May 2017 Eli Lilly plans a phase I trial in Healthy volunteers in United Kingdom (IV) (NCT03148431)